Company Uplists to NASDAQ
NEW YORK, NY / ACCESSWIRE / July 13, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small cap and microcap public companies, today announced that it has issued an update note on Aethlon Medical, Inc. (AEMD). On July 8, 2015, Aethlon announced that the NASDAQ approved its application to list its common stock on the NASDAQ Capital Market. Shares reacted quickly to the news, which we see as a significant milestone for the company as a NASDAQ listing will increase Aethlon's visibility, liquidity and credibility while expanding its potential institutional investor base. The news comes relatively quickly following a $5.6mn equity raise completed in June, the filing of its annual form 10-K with the SEC, and the April share consolidation highlighted in our May research update on the company. We see nice momentum building for Aethlon and its lead therapeutic candidate the Aethlon Hemopurifier(R).
Aethlon Medical, Inc. ("Aethlon") is a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions.
The note is available here: AEMD Company Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack's. The report will also be available on these platforms.
Highlights from the note are as follows:
Aethlon's uplist to NASDAQ marking major milestone
On July 8, 2015, Aethlon announced that its shares would be uplisting to the NASDAQ Capital Market. Clearly the move to NASDAQ represents a significant accomplishment for the company, which has been striving for this goal for some time. We expect the transition to have a positive effect on Aethlon's liquidity, improve the company's visibility, and also open up the company to new potential mutual funds, pensions and other institutional investors who may have been restricted from investing in the company while it traded on the OTC Marketplace. Aethlon will begin trading on the NASDAQ at the market open on Monday, July 13, 2015, under its existing symbol: AEMD.
$6mn financing secures capital for next round of development
Likely as part of the lead up to qualifying for NASDAQ listing, Aethlon announced an equity raise on June 24, 2015, in a public stock offering led by Roth Capital that netted the company $5.6mn. The raise is a material amount for Aethlon, and should provide the company with sufficient resources to fund its operating and development plan for fiscal 2016E, in conjunction with cash on hand and expected monies from government contracts – although we note the company will likely need to raise additional capital to fund future clinical trials.
Continued expansion of Hemopurifier(R) potential applications
On the clinical development front, Aethlon announced on June 4, 2015, that it has entered into an agreement with the National Institute of Virology (NIV) to begin testing of the Aethlon Hemopurifier(R) as a candidate to treat Chikungunya, a debilitating mosquito-borne virus that is not addressed with proven antiviral drug or vaccine therapies. The announcement is the latest in a series of infectious disease applications for the Hemopurifier(R), a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Hemopurifier(R) was listed as one of the 11 most remarkable medical advances in 2014, according to Time magazine and appears to be emerging as a first-line countermeasure against viruses that are not addressed with proven drug therapies, and has been successfully administered to individuals infected with Ebola virus (Ebola), Hepatitis C virus (HCV) and the Human Immunodeficiency virus (HIV).
Aethlon price target remains $26.00
We continue to monitor Aethlon and its lead therapeutic candidate, the Aethlon Hemopurifier(R) and maintain our price target of $26.00.
Please review important disclosures on our website at www.seethruequity.com.
About Aethlon Medical, Inc.
Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders. The company's lead product is the Aethlon Hemopurifier(R), a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders. Additional information can be found online at www.AethlonMedical.com.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.
For more information visit www.seethruequity.com.